Katie Wright, Author at European Medical Journal - Page 8 of 45

Ketamine Reduces Inflammation After Liver Resection

The study explored the anti-inflammatory and analgesic effects of low-dose ketamine and Dex, both commonly used anaesthetic agents with known immune-modulating properties.

Ear-Clip Device Boosts Fitness in Adults via Vagus Nerve Stimulation

Vagus nerve stimulation significantly boosts fitness and reduces inflammation, UK trial finds. Discover if it could benefit you.

Doxycycline After Sex Significantly Reduces Bacterial STI Risk

Taking doxycycline after condomless sex significantly reduced bacterial STIs in men who have sex with men and transgender women.

HPV Vaccine Significantly Reduces Actinic Keratosis Lesions

Results from the 12-month double-blind, placebo-controlled trial revealed that the vaccinated group consistently experienced greater reductions in AK lesions than the control group.

Gecko-Inspired Nanoparticles Revolutionise Bladder Cancer Treatment

A new study offers an innovative solution inspired by nature: soft dendritic particles (SDPs) that mimic the adhesive properties of gecko feet.

Diffusion MRI Predicts Breast Cancer Response Early in Chemotherapy

A recent prospective study has directly compared different diffusion MRI parameters over the course of NAC to assess their ability to predict pathologic complete response.

Global Study Finds No Overall Link Between Gestational Diabetes and Breast Cancer

Although the link between Type 2 diabetes and increased breast cancer risk is well established, the relationship between GDM and breast cancer has remained unclear.

Emerging Melanoma Vaccines Offer Hope for Advanced Patients

These vaccines work by activating the immune system to recognise and attack tumour cells, while also creating immune memory for long-term protection.

Urodynamics Offers No Added Benefit for Bladder Care

From an economic perspective, urodynamics added £463 in cost and yielded a modest 0.011 additional quality-adjusted life-years.

Postbiotics Show Promise in Slowing Liver Fibrosis

While the primary outcome, a ≥10% reduction in α-SMA, was reached in 29% of ReFerm® recipients versus 14% in the control group, the difference was not statistically significant.